Health&Life Co

Health&Life Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Health&Life Co (1781.TWO) as of Nov 6, 2026 is -22.51. In the previous year, Cash Conversion Cycle (CCC) was 60.15 — a change of -137.43% (lower).

Cash Conversion Cycle

-22.51

YoY

-137.43%

Last updated:

Cash Conversion Cycle (CCC) of Health&Life Co is 2025 -22.51 . Cash Conversion Cycle (CCC) of Health&Life Co was 2024 60.15 . It decreases by -137.43% lower compared to the previous year.

The Health&Life Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
43.09 TWD
Jan 1, 2019
14.18 TWD
Jan 1, 2020
20.56 TWD
Jan 1, 2021
73.83 TWD
Jan 1, 2022
99.30 TWD
Jan 1, 2023
72.62 TWD
Jan 1, 2024
60.15 TWD
Jan 1, 2025
-22.51 TWD
The Health&Life Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-22.51-137.43%
60.15-17.17%
72.62-26.87%
99.30+34.50%
73.83+259.15%
20.56+44.99%
14.18-67.10%
43.09+250.50%
12.29-74.14%
47.55+7.11%
44.39-64.05%
123.49—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Cash Conversion Cycle (CCC) of Health&Life Co is -22.51 in 2025.

Cash Conversion Cycle (CCC) of Health&Life Co changed from 60.15 to -22.51, representing a -137.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Health&Life Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Health&Life Co

All Key Metrics — Health&Life Co